20 articles
New mouse research finds the trendy D+Q senolytic combo severely damages myelin, raising red flags for longevity self-experimenters.
Dasatinib and quercetin, a leading senolytic combo, unexpectedly reduced myelination in healthy mouse brains, mimicking multiple sclerosis damage.
A Merck-Kelun antibody-drug conjugate paired with immunotherapy slashed tumor progression risk in untreated advanced lung cancer patients.
Belzutifan plus pembrolizumab wins FDA approval for high-risk kidney cancer after surgery, slashing recurrence risk in a landmark phase III trial.
A US phase II trial confirms darolutamide combined with ADT dramatically improves survival in metastatic hormone-sensitive prostate cancer.
A phase III trial shows daraxonrasib doubled overall survival vs chemotherapy in metastatic pancreatic cancer, signaling a new standard of care.
Zoldonrasib targets a previously undruggable KRAS mutation, showing 52% response rate and 11-month progression-free survival in NSCLC.
Daraxonrasib targets RAS mutations in pancreatic cancer, showing 35% response rates and 13-month survival — far outpacing current chemo options.
Trastuzumab deruxtecan wins two new FDA approvals for early HER2+ breast cancer, showing dramatic survival gains over standard therapy.
A TROP2-targeting antibody-drug conjugate added to pembrolizumab slashed disease progression risk in PD-L1-positive lung cancer patients.
A Phase 1b trial drug may prevent post-surgical liver failure by accelerating liver regeneration, expanding options for cancer patients.
A clinical trial combining vopimetostat and daraxonrasib shows durable responses in most pancreatic cancer patients treated.
Daraxonrasib nearly doubled median survival in pancreatic cancer patients, offering real hope for one of oncology's deadliest diagnoses.
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
The EMERALD-3 trial shows STRIDE plus TACE improved progression-free survival to 13 months vs 9.8 months, but with significantly more side effects.
Daraxonrasib nearly doubled survival vs. standard chemo in a major ASCO trial — a potential turning point for one of cancer's deadliest diagnoses.
Selpercatinib slashed recurrence risk in RET fusion-positive lung cancer patients post-surgery, achieving 92% vs 61% 2-year survival.
A small Brazilian trial found 43% of women taking 2,000 IU vitamin D daily achieved complete cancer remission vs 24% on placebo.
Elisrasib achieved 60% response rates in treatment-naive NSCLC patients and helped one-third who failed prior KRAS therapies.
A major RCT shows finerenone reduces kidney function loss by 23% in non-diabetic CKD patients, expanding its protective role beyond diabetes.
